Company Overview - Health Road (02587.HK) closed at HKD 10.3 per share, up 8.08% with a trading volume of 119 million shares and a turnover of HKD 1.197 billion, showing a volatility of 10.07% [1] - Over the past month, Health Road has seen a cumulative increase of 7.08%, but a year-to-date decline of 27.14%, underperforming the Hang Seng Index which has risen by 25.45% [1] - As of December 31, 2024, Health Road reported total revenue of HKD 1.201 billion, a year-on-year decrease of 3.51%, and a net profit attributable to shareholders of -HKD 268 million, an increase of 13.42% year-on-year, with a gross margin of 30.47% and a debt-to-asset ratio of 59.82% [1] Industry Analysis - Currently, there are no institutional investment ratings for Health Road [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -10.95 times, with a median of 0.36 times. Health Road's P/E ratio stands at -28.85 times, ranking 66th in the industry [2] - Competitors' P/E ratios include: Other Star Medical Holdings (02393.HK) at 0.35 times, Jingjiu Health (00648.HK) at 0.37 times, Yihui Group (08161.HK) at 2.32 times, Global Medical (02666.HK) at 5.14 times, and Ruici Medical (01526.HK) at 5.2 times [2] Business Position - Health Road operates a digital health service platform in China and is the fourth largest digital health service platform based on registered personal users as of December 31, 2023, and the fifth largest based on revenue for 2023 [2] - Since 2001, the company has provided health services to individual users on its digital platform and expanded to offer corporate services and digital marketing since 2015, playing a significant role in the digital transformation of China's health and wellness industry over the past 20 years [2] Important Dates - The company is scheduled to disclose its mid-year report for the fiscal year 2025 on August 29, 2025 [3] - On August 15, 2025, Best Premier Group Investment Limited reduced its holdings by 3 million shares at an average price of HKD 7.6 per share, now holding 85.23 million shares, representing 9.71% of total shares [3]

Company Overview - Health Road Holdings Limited operates a digital health service platform in China and is the fourth largest digital health service platform by registered personal users as of December 31, 2023 [2] - The company is also the fifth largest digital health service platform by revenue for the year 2023 [2] - Since 2001, the company has provided health services to individual users on its digital platform and expanded to offer enterprise services and digital marketing since 2015 [2] Financial Performance - As of December 31, 2024, the company reported total revenue of 1.201 billion yuan, a year-on-year decrease of 3.51% [1] - The net profit attributable to shareholders was -268 million yuan, an increase of 13.42% year-on-year [1] - The gross profit margin stood at 30.47%, with a debt-to-asset ratio of 59.82% [1] Market Performance - As of July 14, the stock price of Health Road was 8.77 HKD per share, reflecting a 13.6% increase with a trading volume of 216 million shares and a turnover of 1.831 billion HKD [1] - Over the past month, the stock has experienced a cumulative decline of 86.59%, and a year-to-date decline of 40.98%, underperforming the Hang Seng Index by 20.34% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.89 times, with a median of 1.17 times [1] - Health Road's P/E ratio is -23.37 times, ranking 68th in the industry [1] - Other companies in the industry have P/E ratios such as Giant Star Medical Holdings at 0.28 times, Jingjiu Health at 0.38 times, and others ranging from 1.96 to 5.45 times [1] Analyst Ratings - Liao Asset Management has given a "Buy" rating for Health Road, with a target price of 68.5 HKD [1]

Company Overview - Health Road Holdings Limited operates a digital health service platform in China, ranking as the fourth largest by registered personal users and fifth largest by revenue as of 2023 according to Frost & Sullivan [3] - The company has been providing health services on digital platforms since 2001 and expanded to offer enterprise services and digital marketing since 2015, playing a significant role in the digital transformation of the health and wellness industry in China over the past 20 years [3] Financial Performance - As of December 31, 2024, Health Road reported total revenue of 1.201 billion yuan, a year-on-year decrease of 3.51%, while the net profit attributable to shareholders was -268 million yuan, an increase of 13.42% [2] - The gross profit margin stood at 30.47%, and the debt-to-asset ratio was 59.82% [2] Stock Performance - Over the past month, Health Road's stock has increased by 58.77%, and year-to-date, it has surged by 284.17%, outperforming the Hang Seng Index's increase of 19.82% [2] - As of June 13, the stock closed at 55.05 HKD per share, with a trading volume of 4.393 million shares and a turnover of 238 million HKD, showing a volatility of 18.61% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -21.62 times, with a median of 0.39 times [2] - Health Road's P/E ratio is -152.14 times, ranking 54th in the industry, compared to other companies such as Jingjiu Health (0.38 times), Giant Star Medical Holdings (0.4 times), and others [2]

6月9日，截至港股收盘，恒生指数上涨1.63%，报24181.43点。健康之路（02587.HK）收报59.85港元/ 股，上涨15.21%，成交量165.45万股，成交额9556.87万港元，振幅18.48%。 最近一个月来，健康之路累计涨幅74.92%，今年来累计涨幅297.17%，跑赢恒生指数18.61%的涨幅。 财务数据显示，截至2024年12月31日，健康之路实现营业总收入12.01亿元，同比减少3.51%；归母净利 润-2.68亿元，同比增长13.42%；毛利率30.47%，资产负债率59.82%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.27倍，行业中值0.3倍。健康之路 市盈率-157.29倍，行业排名第54位；其他巨星医疗控股（02393.HK）为0.22倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为3.78倍、环球医疗（02666.HK）为4.66倍、瑞慈医疗 （01526.HK）为5.15倍。 资料显示，健康之路股份有限公司于中国经营数字健康医疗服务平台。根据弗若斯特沙利文的资 ...